The Psychopharmacologic Drugs Advisory Committee and the Peripheral & Central Nervous System Drugs Advisory Committee will discuss Otsuka Pharmaceutical and Lundbeck’s supplemental New Drug Application (sNDA) 205422-s009, efficacy supplement for REXULTI (brexpiprazole) tablets, for proposed treatment of agitation associated with Alzheimer’s dementia at a meeting being held virtually on April 14 at 9 am. Webcast Link
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OTSKF:
- FDA to hold a joint committee meeting
- Otsuka upgraded to Buy from Hold at Jefferies
- Otsuka upgraded to Neutral from Sell at Goldman Sachs
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue